It induced in vivo tumor regressions in DLBCL xenografts (OCILY10 and TMD8) and PDX models expressing Bfl-1.103 A combination of AZD4573 and c-MYC inhibitor 10,058-F4 can effectively suppress araC-resistant AML.119. Here, MYC is linked to neoplasm.